FM101 is a selective adenosine A3 receptor modulator developed for various indications, including glaucoma and non-alcoholic fatty liver disease.[1][2][3]

References

  1. ↑ Jayanetti, Viran; Sandhu, Sartaj; Lusthaus, Jed A. (20 November 2020). "The Latest Drugs in Development That Reduce Intraocular Pressure in Ocular Hypertension and Glaucoma". Journal of Experimental Pharmacology. 12: 539–548. doi:10.2147/JEP.S281187. PMC 7685378. PMID 33244278.
  2. ↑ Park, JeongSu; Choi, Su-Yeon; Wang, Feng; Park, Chong-Woo; Lee, Jiyoun; Lee, Hyuk-Woo; Roh, Yoon-Seok (April 2020). "Imbalance Between α1‐Antitrypsin and Neutrophil Elastase in Simple Steatosis Promotes Inflammation and Fibrosis Through Regulation of Adenosine a3 Receptor Signaling in Non‐alcoholic Steatohepatitis". The FASEB Journal. 34 (S1): 1. doi:10.1096/fasebj.2020.34.s1.03837. S2CID 219099467.
  3. ↑ Park, Chong-Woo; Han, Chung-Tack; Sakaguchi, Yasue; Lee, Jiyoun; Youn, Hwa-young (12 February 2020). "Safety evaluation of FM101, an A3 adenosine receptor modulator, in rat, for developing as therapeutics of glaucoma and hepatitis". EXCLI Journal. 19: 187–200. doi:10.17179/excli2019-2058. ISSN 1611-2156. PMC 7105940. PMID 32256265.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.